达格列净联合黄连素治疗脆性2型糖尿病的临床观察

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (847 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Dapagliflozin combined with Berberine in the treatment of fragile type 2 diabetes. Methods A selection of 60 patients with fragile type 2 diabetes who were admitted to Huai’an Cancer Hospital in Jiangsu Province from April 2018 to March 2020 were randomly divided into observation group (30 cases) and control group (30 cases) by coin flipping. The control group was given intensive insulin therapy alone, and the observation group was treated with Dapagliflozin + Berberine. The lipid metabolism and body mass index (triacylglycerol [TG], total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], body weight [BW], body mass indexes [BMI]) before and after treatment between the two groups were compared, and treatments changes in blood glucose and insulin control indicators (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], 2 h postprandial blood glucose [2hPG], fasting insulin [FINS], C peptide [CP]), blood glucose fluctuations (postprandial blood glucose fluctuation amplitude [PPGE], mean absolute difference of blood sugar [MODD], standard deviation of blood sugar level [SDBG]), blood pressure and daily use of insulin [systolic blood pressure (SBP), diastolic blood pressure (DBP), daily use of insulin] were compared before and after treatment. The occurrence of adverse reactions between the two groups was compared. Results After treatment, the levels of TG, TC, LDL-C, BW, and BMI in the two groups were lower than before treatment, while the observation group were lower than the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the levels of HbA1c, FPG, and 2hPG in the two groups were lower than before treatment, while FINS and CP were higher than before treatment, and the levels of HbA1c, FPG, and 2hPG in the observation group were lower than those in the control group, while FINS and CP were higher than those in the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, PPGE, MODD, and SDBG in the two groups were lower than before treatment, while the observation group were lower than the control group, and the differences were statistically significant (P ＜ 0.05). After treatment, the daily consumption levels of SAP, DAP, and daily use of insulin in the two groups were lower than before treatment, while the observation group were lower than the control group, and the differences were statistically significant (P ＜ 0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Dapagliflozin combined with Berberine has a significant effect in the treatment of patients with fragile type 2 diabetes, which can improve blood sugar levels and has high drug safety.

Key words： Dapagliflozin Berberine Fragile type 2 diabetes Blood glucose

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Jie WU Xinhua MA Liming YAN Yan SHI Wen LI Hang ZHU Ping

Cite this article:

ZHOU Jie WU Xinhua MA Liming YAN Yan SHI Wen LI Hang ZHU Ping. Clinical observation of Dapagliflozin combined with Berberine in the treatment of fragile type 2 diabetess[J]. 中国医药导报, 2021, 18(15): 75-78,83.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I15/75

[1] 张德园，钟兴，潘天荣.达格列净对血糖控制不佳的2型糖尿病患者肾脏保护作用的研究[J].中国糖尿病杂志，2019，27（11）：806-811.
[2] 刘敏，李忠东，张瑞麟.对2型糖尿病病人药学服务切入点的探索[J].药学服务与研究，2015，15（5）：343-346.
[3] 李国英，程千鹏，张蕙，等.糖尿病合并持续植物状态胰岛素注射患者低血糖的发生情况[J].中国医药导报，2019， 16（27）：69-72.
[4] 李国生，刘栩晗，李欣宇，等.黄连素调节BMP4转录通路基因表达改善2型糖尿病地鼠内脏白色脂肪组织胰岛素抵抗的研究[J].中国中药杂志，2016，41（3）：514-520.
[5] 刘新民.实用内分泌学[M].北京：人民军医出版社，1997：356-358.
[6] 王斌，王幼辉，吴深涛.2型糖尿病患者胰岛功能与血糖波动的相关性研究[J].安徽医科大学学报，2019，54（8）：1258-1262.
[7] Luo N，Zhu Y，Zhang Z，et al. Clinical observation on the combined therapy of sitagliptin with insulin for patients with brittle diabetes [J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban，2015，40（10）：1089-1095.
[8] 杨艳玲，汤云昭，倪长霖.达格列净联合二甲双胍与吡格列酮治疗2型糖尿病的临床观察[J].中国慢性病预防与控制，2019，27（8）：611-614.
[9] 董玲，靳秋露，马洪飞.老年脆性糖尿病多学科联合诊治的意义[J].齐鲁医学杂志，2017，32（4）：85-87.
[10] Stella CP，Umar D，Yaseen A，et al. Long Esop-hageal Stricture in a Brittle Diabetic [J]. Euroasian J Hepatogastroenterol，2017，7（2）：191-192.
[11] 程彦臻，陈宏，杨帆，等.广东省超重、肥胖2型糖尿病患者慢性并发症及合并症发病情况调查[J].山东医药，2016，56（31）：52-54.
[12] 杨毅，韩晨阳，张晓玲，等.达格列净联合甲钴胺对2型糖尿病周围神经病变的治疗效果[J].中国慢性病预防与控制，2017，25（11）：872-874.
[13] 邓宁，胡庆芬，梁彩虹，等.达格列净片联合盐酸二甲双胍对2型糖尿病患者的临床研究[J].中国临床药理学杂志，2019，35（18）：2016-2018.
[14] 陈小青，王丽萍.黄连素在代谢综合征及相关疾病中的研究进展[J].中国中西医结合肾病杂志，2015，16（1）：88-91.
[15] 吴林根，王燕，朱峥，等.黄连素干预对代谢综合征及心脑血管疾病影响[J].心脏杂志，2015，27（3）：348-352.
[16] 邓晓威，谢宁.黄连素通过抑制MicroRNA-29a的表达改善胰岛素抵抗[J].中医药学报，2016，44（1）：45-48.
[17] Yabe D，Hamamoto Y，Seino Y，et al. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes：a drug safety evaluation [J]. Expert Opin Drug Saf，2017，16（10）：1211-1218.
[18] 李骋，何金枝，周学东，等.黄连素调控胰岛素抵抗相关2型糖尿病的研究进展[J].中国中药杂志，2017，42（12）：2254-2260.
[19] 魏雪芳，杨煜.达格列净联合胰岛素强化治疗对新诊断2型糖尿病患者的效果[J].中外医学研究，2021，19（1）：134-136.
[20] 宋青青，劳斌昌，黄春，等.达格列净对2型糖尿病合并肥胖患者脂联素与瘦素水平影响[J].现代医院，2020， 20（8）：1215-1217，1220.
[21] 冷蔚玲，梁自文.达格列净对糖尿病血管并发症的影响研究进展[J].医学综述，2016，22（18）：3628-3632.
[22] 叶冠伦，罗卓章，梁栋伟.达格列净对肥胖2型糖尿病患者脂肪组织、Lp-PLA2、hs-CRP的影响[J].中国医学创新，2020，17（20）：5-10.
[23] 陈耿钦.达格列净对2型糖尿病合并代谢综合征患者糖脂代谢和氧化应激指标的影响[J].中国医药科学，2021， 11（3）：119-122.
[24] Scheen AJ. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes [J]. Clin Pharmacokinet，2017，56（7）：703-718.
[25] 王薇，张婷婷，贾冰，等.达格列净片对糖尿病肾病患者尿蛋白的影响[J].中国临床药理学杂志，2019，35（10）：946-949.
[26] 王丹，谷晓岚，田雨.达格列净联合利拉鲁肽治疗2型糖尿病的效果[J].中国当代医药，2020，27（20）：69-72.
[27] 丁大法，万丽丽，张琳琳，等.达格列净联合胰岛素对脆性糖尿病血糖波动影响的观察研究[J].中华内分泌代谢杂志，2018，34（10）：844-847.